Myoma

(redirected from uterine myoma)
Also found in: Dictionary, Thesaurus, Medical.
Related to uterine myoma: ovarian cyst, nabothian cyst, adenomyosis

myoma

[mī′ō·mə]
(medicine)
A benign uterine tumor composed principally of smooth muscle cells.
Any neoplasm originating in muscle.

Myoma

 

a benign tumor of muscle tissue. A myoma that develops from smooth muscle (uterus, intestine, stomach, skin) is called a leiomyoma; a myoma forming from striated skeletal or heart muscle is a rhabdomyoma. Leiomyomas of the stomach and intestine and rhabdomyomas are rare; they are found accidentally during surgery or in autopsies. Besides muscle fibers, a myoma usually contains connective tissue and resembles a fibromyoma.

Myomas (fibromyomas) of the uterus are very common. The tumors are generally multiple and consist of individual nodules of different sizes and shapes. Some tumors weigh several kilograms. Fibromyomas of the uterus result from hormonal disturbances related to ovarian function. They occur most often in women over 30 years of age. Myomas may cause prolonged bleeding, which is followed by anemia and compression of the urinary bladder, blood vessels, and nerves of the minor pelvis. The tumor continues to grow until menstruation ceases, usually when the woman is between the ages of 50 and 55. If a tumor is discovered, the woman should be examined by a physician three or four times a year. Surgery is indicated if the tumor is large or exhibits rapid growth and if the bleeding does not respond to conservative treatment.

REFERENCES

Petchenko, A. I. Fibromiomy matki. Kiev, 1958.
Giliazutdinova, Z. Sh. K patogenezu fibromiomy matki. Kazan, 1967.
Persianinov, L. S. Operativnaia ginekologiia. Moscow, 1971.

L. S. PERSIANINOV

Mentioned in ?
References in periodicals archive ?
Its most advanced product, PGL4001 Esmya(TM), completed Phase III clinical trials in June 2010 for the treatment of uterine myoma, a common benign tumor in women of reproductive age.
Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT.
Primary physical examinations revealed a mobile solid mass of nearly 12-14 cm in diameter, which couldn't be differentiated from a uterine myoma.
Cetrorelix has successfully completed a broad seven-Phase 2 program in BPH, endometriosis, and uterine myoma.
Its extensive portfolio, from drug discovery to marketed products, includes perifosine, an orally-active AKT inhibitor in several Phase II trials for multiple cancers, and cetrorelix, an LHRH antagonist already marketed for in vitro fertilisation under the brand name Cetrotide(R), and also in advanced clinical development for the treatment of uterine myoma, endometriosis and benign prostatic hyperplasia (BPH).
The Series B will enable the development of a molecule licensed-in from privately-held French company, HRA Pharma, for the pre-operative treatment of uterine myoma.
Its extensive portfolio, from drug discovery to marketed products, includes perifosine, an orally-active AKT inhibitor in several Phase II trials for multiple cancers, and cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide(R), and also in advanced clinical development for the treatment of uterine myoma, endometriosis and benign prostatic hyperplasia (BPH).
Broad, seven-study Phase II program on cetrorelix in BPH, endometriosis and uterine myoma now successfully completed.
Cetrorelix has successfully completed a broad 7-Phase II program in BPH, endometriosis, and uterine myoma.